- Home
- HYPR vs DXR Comparison
HYPR vs DXR Comparison
Compare HYPR & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- DXR
- Stock Information
- Founded
- HYPR 2014
- DXR 1970
- Country
- HYPR United States
- DXR United States
- Employees
- HYPR N/A
- DXR N/A
- Industry
- HYPR Medical Specialities
- DXR Medical/Dental Instruments
- Sector
- HYPR Health Care
- DXR Health Care
- Exchange
- HYPR Nasdaq
- DXR Nasdaq
- Market Cap
- HYPR 55.9M
- DXR 46.1M
- IPO Year
- HYPR N/A
- DXR N/A
- Fundamental
- Price
- HYPR $1.08
- DXR $10.14
- Analyst Decision
- HYPR Strong Buy
- DXR Strong Buy
- Analyst Count
- HYPR 3
- DXR 1
- Target Price
- HYPR $1.06
- DXR $25.00
- AVG Volume (30 Days)
- HYPR 459.6K
- DXR 3.3K
- Earning Date
- HYPR 08-07-2025
- DXR 01-01-0001
- Dividend Yield
- HYPR N/A
- DXR N/A
- EPS Growth
- HYPR N/A
- DXR 86.16
- EPS
- HYPR N/A
- DXR 0.11
- Revenue
- HYPR $11,732,000.00
- DXR $119,714.00
- Revenue This Year
- HYPR $12.31
- DXR N/A
- Revenue Next Year
- HYPR $29.29
- DXR N/A
- P/E Ratio
- HYPR N/A
- DXR $93.33
- Revenue Growth
- HYPR 0.34
- DXR N/A
- 52 Week Low
- HYPR $0.53
- DXR $6.55
- 52 Week High
- HYPR $1.90
- DXR $10.14
- Technical
- Relative Strength Index (RSI)
- HYPR 66.05
- DXR 65.31
- Support Level
- HYPR $0.91
- DXR $9.05
- Resistance Level
- HYPR $1.20
- DXR $9.90
- Average True Range (ATR)
- HYPR 0.09
- DXR 0.29
- MACD
- HYPR 0.03
- DXR 0.02
- Stochastic Oscillator
- HYPR 72.73
- DXR 100.00
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.